Investors

Overview

CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies covering a spectrum of blood-related cancers that offer a unique benefit to patients and healthcare providers. CTI BioPharma has a late-stage development pipeline, including pacritinib, CTI BioPharma’s lead product candidate for the treatment of patients with myelofibrosis. CTI BioPharma is headquartered in Seattle, Washington. Our management and investor relations team provide updates throughout the year through conference calls, investor events, press releases and SEC filings. We invite you to sign up for our investor alerts and listen to our archived and live presentations.

To CTI’s knowledge, all press releases, scientific papers and abstracts, and the information contained within them were timely and accurate when issued. The continued accuracy of this material beyond the date of issuance and posting on the website is not assured. CTI has no intention of updating this information and specifically disclaims any duty to do so. These documents may contain forward-looking statements. Actual results could vary dramatically as a result of known and unknown risks and uncertainties. Please see Terms of Use for this website.

IR Contact

 
  • Current Quote
  • Stock Chart
NASDAQ:CTIC
$1.56 - 0.09 (5.45%)
Day High:$1.68
Day Low:$1.55
Volume:106,631
11/20/184:00 p.m. ET
Delayed at least 15 minutes.

Julia Balanova
Ph + 646 378 2936
jbalanova@soleburytrout.com


 

Recent News

MORE
DateTitle 
Nov 01, 2018CTI BioPharma Reports Third Quarter 2018 Financial Results
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time- SEATTLE, Nov. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today reported financial results for the third quarter and nine months ended September 30, 2018. In October 2018, CTI BioPharma announced the continuation of the PAC203 Phase 2 study without modification, following a planned second interim review by an Independent Data Monitoring Committee (IDMC). The IDMC did not identify significant drug- or... 
Printer Friendly Version
Oct 25, 2018CTI BioPharma to Report Third Quarter 2018 Financial Results on November 1, 2018
SEATTLE, Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ: CTIC) today announced that management plans to report its third quarter 2018 financial results on Thursday, November 1, 2018, after the close of the U.S. financial markets. Following the announcement, members of the management team will host a webcast conference call to discuss the results and provide a general corporate update at 4:30 p.m. ET (1:30 p.m. PT). Access to the event can be obtained as follows: Thurs... 
Printer Friendly Version
Oct 01, 2018CTI BioPharma Announces the Continuation of PAC203 Study Following Interim Data Review
- Trial to continue to full enrollment of all three treatment arms - - Full data set expected to support determination of an optimal dose for planned Phase 3 development in patients with severe thrombocytopenia - - Independent Data Monitoring Committee did not identify significant safety concerns - SEATTLE, Oct. 1, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) today announced that following a planned second interim data review of the PAC203 study by the Independent Data Monit... 
Printer Friendly Version

Events

MORE
There are currently no events scheduled.
Data provided by Nasdaq. Minimum 15 minutes delayed.